Capricor Therapeutics, Inc. (CAPR, Financial) experienced a significant stock decline of 5.09%, trading at $13.61 with a volume of 456,003 shares. The biotech company reported revenue of $2.26 million and a net loss of $12.56 million, with an EPS of -$0.38. The price-to-earnings ratio stands at -13.38. Despite the decline, all seven rating firms recommend buying the stock, with no hold or sell ratings.
In the broader biotech sector, which fell by 0.67%, stocks such as Cardio Diagnostics Holdings and Innate Pharma saw gains, while Aptevo Therapeutics and Palisade Bio were active. Capricor focuses on cell and exosome therapies, notably CAP-1002 and deramiocel for Duchenne muscular dystrophy, using its StealthXTM platform for preclinical vaccine research.
